Ionis Pharmaceuticals reported a challenging fourth quarter and full year 2025, characterized by increased operating expenses and a net loss, despite growth in commercial revenue driven by new product launches. The company is investing heavily in its pipeline and upcoming launches, with a focus on achieving cash flow breakeven in 2028.
Total revenue for the year ended December 31, 2025, was $944 million, a 34% increase from $705 million in 2024, exceeding expectations.
positiveTRYNGOLZA® (olezarsen) generated $50 million in net product sales in Q4 2025, a 56% increase over the prior quarter, and $108 million for the full year 2025.
positiveCash, cash equivalents and short-term investments increased to $2.7 billion as of December 31, 2025, up from $2.3 billion in the prior year.
positiveMultiple key programs are on track for 2026 launches and regulatory submissions, including olezarsen for sHTG and zilganersen for Alexander disease.
positiveLoss from operations for the year ended December 31, 2025, was $382 million, compared to a loss of $475 million in 2024, indicating continued operational losses.
negativeTotal operating expenses increased to $1,326 million in 2025 from $1,180 million in 2024, driven by investments in commercialization efforts for new product launches.
attentionNon-GAAP operating loss for the year ended December 31, 2025, was $248 million, compared to $345 million in 2024, still reflecting a significant loss.
negativeThe company anticipates its non-GAAP operating loss to be similar to 2025 in 2026, excluding the one-time sapablursen upfront payment, indicating a continued period of unprofitability.
attentionThe company expects cash, cash equivalents and short-term investments to be approximately $1.6 billion by the end of 2026, a decrease from $2.7 billion at the end of 2025.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Commercial revenue | N/A | — | — | — |
Research and development revenue | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026.
This year, we are poised for two additional independent launches of groundbreaking therapies — olezarsen for severe hypertriglyceridemia, our first launch in a broad patient population, and zilganersen for Alexander disease, our first launch from our leading neurology pipeline.
In 2025 we exceeded our revenue guidance, driven by growing commercial revenue from our independent launches and substantial R&D revenue from continued pipeline success.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.